Equity · Healthcare
CABA
NASDAQCabaletta Bio (CABA)
The line runs 2.84 USD on 12 August through 1.50 USD on 9 November, on a scale from 1 to 4. Days the market did not trade hold the previous close, flat.
- Market cap
- 323.6M USD
- EPS, diluted, year to Dec 2025
- −2.10 USD
- 52-week range
- 1.26 USD – 4 USD
- Avg volume
- 380.9K
as of Nov 9, 2026
Have Cabaletta Bio (CABA) insiders bought or sold shares recently?
CABA's newest Form 4 filing is dated 21 January 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 21 Jan 2026 | Chang David J.Chief Medical Officer | Buy | 8,800 | 20K USD |
| 21 Jan 2026 | Binder GwendolynPresident, Science & Tech. | Buy | 11,312 | 25K USD |
| 21 Jan 2026 | Tomasello ShawnDirector | Buy | 22,725 | 50K USD |
| 21 Jan 2026 | Gavel SteveChief Commercial Officer | Buy | 22,170 | 50K USD |
| 21 Jan 2026 | Bollard CatherineDirector | Buy | 4,405 | 10K USD |
| 21 Jan 2026 | Nichtberger StevenPresident & CEO | Buy | 45,000 | 101K USD |
| 21 Jan 2026 | Simon MarkDirector | Buy | 11,061 | 25K USD |
| 21 Jan 2026 | Gerard MichaelGeneral Counsel | Buy | 6,600 | 15K USD |
| Bought | 8 open-market purchases | 132,073 | $296K |
1 other filing: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 13 Oct 2025 | Gavel SteveCHIEF COMMERCIAL OFFICER | Award | 275,000 |
Which funds hold Cabaletta Bio (CABA)?
6 of the 45 institutional funds we track reported a Cabaletta Bio position for the quarter ended 30 Jun 2026 — a combined 31.7M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | New position | 3,522,112 | 11.0M USD | |
| Millennium Management | Trimmed | 2,068,491 | 6.4M USD | −65.0% |
| Marshall Wace | Trimmed | 1,565,939 | 4.9M USD | −28.2% |
| Renaissance Technologies | Held (±25%) | 1,535,300 | 4.8M USD | −24.6% |
| Two Sigma Investments | Trimmed | 1,410,931 | 4.4M USD | −43.5% |
| D. E. Shaw & Co. | Trimmed | 90,652 | 282K USD | −52.1% |
| Balyasny Asset Management | Exited | |||
| Point72 Asset Management | Exited |
What has been filed or recorded for Cabaletta Bio (CABA)?
The filings we hold for Cabaletta Bio, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,695 shares | 7K USD notional · 0.002% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 809 shares | 2K USD notional · <0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 962 shares | 2K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.28 USD | |
| 30 Sep 2026 | Financials | Total assets | 336.5M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 283.9M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.34 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.39 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.10 USD | |
| 31 Dec 2025 | Financials | Net income | −167.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.10 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.44 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.73 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.71 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.34 USD |
What do people ask about Cabaletta Bio (CABA)?
What did Cabaletta Bio shares close at?1.50
Cabaletta Bio closed at 1.50 USD on 9 Nov 2026, up 16.28% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Cabaletta Bio’s market cap?323.6M
Cabaletta Bio is worth 323.6M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Cabaletta Bio insiders bought or sold shares recently?
No Cabaletta Bio insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 21 Jan 2026 (SEC Form 4). See Insiders
Which funds own Cabaletta Bio?6 of 45
6 of the 45 funds we track reported a Cabaletta Bio position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Millennium Management and Marshall Wace. See Funds
When did Cabaletta Bio last report earnings?−0.28
Cabaletta Bio last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.28 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings